NOMOCAN PHARMACEUTICALS LLC
SBIR Phase I award from Department of Health and Human Services.
Summary
Nomocan Pharmaceuticals LLC received nearly $500,000 from the National Institutes of Health to develop new treatments or prevention methods for childhood cancers and rare cancers. This SBIR Phase I award supports early-stage research into therapeutic technologies.
- Amount
- $499,166
- Agency
- Department of Health and Human Services · National Institutes of Health
- Program / Phase
- SBIR · Phase I
- NAICS
- 541715 · RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY)
- Place of performance
- NY
- Period
- 2025-09-15 → 2026-09-14
Technology domains
Human Performance & Medical
Description
PHASE I - DEVELOPMENT OF THERAPEUTIC OR PREVENTATIVE TECHNOLOGIES FOR TREATMENT OR PREVENTION OF PEDIATRIC CANCERS AND/OR RARE CANCERS SBIR CONTRACTRIPTION.